Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tocilizumab by Chugai Pharmaceutical for Septic Shock: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Septic Shock. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Sepsis: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sepsis. According to GlobalData, Phase II...
LUNA-18 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
LUNA-18 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
SAIL-66 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
SAIL-66 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Emicizumab by Chugai Pharmaceutical for Von Willebrand Disease (vWD): Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase I for Von Willebrand Disease (vWD). According to...
Crovalimab by Chugai Pharmaceutical for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Crovalimab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sickle Cell Disease With Vaso-Occlusive Crisis....
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...
SOF-10 by Chugai Pharmaceutical for Gastric Cancer: Likelihood of Approval
SOF-10 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
SOF-10 by Chugai Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
SOF-10 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer. According to...
SOF-10 by Chugai Pharmaceutical for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SOF-10 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
ROSE-12 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
ROSE-12 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
NXT-007 by Chugai Pharmaceutical for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
NXT-007 is under clinical development by Chugai Pharmaceutical and currently in Phase II for Hemophilia A (Factor VIII Deficiency). According...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...